PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsLisdexamfetamine dimesylate
Lisdexamfetamine dimesylate
Lisdexamfetamine Dimesylate, Vyvanse (lisdexamfetamine dimesylate) is a small molecule pharmaceutical. Lisdexamfetamine dimesylate was first approved as Vyvanse on 2007-02-23. It is used to treat attention deficit disorder with hyperactivity and binge drinking in the USA.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
chemically-induced disordersD064419
behavior and behavior mechanismsD001520
mental disordersD001523
Trade Name
FDA
EMA
Lisdexamfetamine dimesylate, Vyvanse
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lisdexamfetamine dimesylate
Tradename
Company
Number
Date
Products
VYVANSETakedaN-021977 RX2007-02-23
7 products, RLD, RS
VYVANSETakedaN-208510 RX2017-01-28
6 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
lisdexamfetamine dimesylateANDA2025-01-30
vyvanseNew Drug Application2023-10-13
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
binge drinking—D063425—
attention deficit disorder with hyperactivityEFO_0003888D001289F90
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N06: Psychoanaleptics
— N06B: Psychostimulants, agents used for adhd and nootropics
— N06BA: Centrally acting sympathomimetics
— N06BA12: Lisdexamfetamine
HCPCS
No data
Clinical
Clinical Trials
124 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Attention deficit disorder with hyperactivityD001289EFO_0003888F90——11—2
HyperkinesisD006948—————1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLisdexamfetamine dimesylate
INN—
Description
Lisdexamfetamine is an amino acid amide.
Classification
Small molecule
Drug classamfetamine derivatives
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CS(=O)(=O)O.CS(=O)(=O)O.C[C@@H](Cc1ccccc1)NC(=O)[C@@H](N)CCCCN
Identifiers
PDB—
CAS-ID608137-32-2
RxCUI700810
ChEMBL IDCHEMBL1201178
ChEBI ID—
PubChem CID11597698
DrugBankDB01255
UNII ID—
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Vyvanse – Takeda
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Vyvanse – Shire
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,211 documents
View more details
Safety
Black-box Warning
Black-box warning for: Lisdexamfetamine dimesylate, Vyvanse
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
16,732 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use